Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repetitive CD34+ Cell Therapy in Dilated Cardiomyopathy
NCT02248532Phase 3Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Jan 2014
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in dilated cardiomyopathy (DCM) and heart failure (HF) (2 arms), sponsored by University Medical Centre Ljubljana. Primary endpoint: Change in left ventricular ejection fraction at 1 year. Started Jan 2014; status: completed.
02
Conditions
dilated cardiomyopathy (DCM)heart failure (HF)
Beyond the preview
Go deeper on NCT02248532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248532.